Kaya, Abdulkadir2023-07-262023-07-2620211309-3878https://doi.org/10.18521/ktd.884764https://hdl.handle.net/20.500.12684/12236Objective: The coronavirus pandemic emerged at the end of 2019 and still affects the whole world, causing severe deaths. The COVID-19 vaccine is highly anticipated, but the emphasis is also given to other vaccines. In this study, the data of 16 cases known having received a pneumococcal vaccine during the COVID-19 period were examined. Methods: Of the 200 COVID-19 cases aged over 65, data of 16 patients who have had pneumococcal vaccination were accessed using the hospital health registry and the national health system records (https://enabiz.gov.tr/). Prognostic factors and COVID-19-related findings of these patients were given in frequency tables. In addition, all raw data were presented in a detailed table. Results: Most of the cases were PCR positive (68.75%), and in 68.75% of the persons, the CT was compatible with COVID-19. Fourteen of the cases were treated by hospitalization. One patient was followed as an outpatient, and one case had already died when brought to the emergency room. Conclusions: Data on cases known to have received the pneumococcal vaccine, which became important during the COVID-19 outbreak, were presented. This work will motivate researchers to conduct large-scale studies.en10.18521/ktd.884764info:eu-repo/semantics/openAccessVaccine; Pneumococcal Vaccine; Covid-19; Coronavirus; PandemicPolysaccharide VaccineArticle13390394WOS:000901301900004N/A